The Supreme Court rules against Novo Nordisk (NVO +1.2%) in an IP dispute with generics drugs...
The Supreme Court rules against Novo Nordisk (NVO +1.2%) in an IP dispute with generics drugs maker Caraco over Novo's Prandin diabetes drug. The verdict allows Caraco to sue Novo to narrow the patent description it gives to the FDA so that it only covers one use rather than three, thus allowing Caraco to enter the market.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs